

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

## Non-Preferred 5-aminosalicylic acid (5-ASA) Oral Agents Step Therapy

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Comments	Quantity Limit
Apriso (mesalamine)	Preferred	May be subject to quantity limit
balsalazide		
sulfasalazine		
sulfasalazine DR		
Asacol HD (mesalamine)	Non-Preferred	
Azulfidine (sulfasalazine) - Brand		
Azulfidine EN (sulfasalazine) – Brand		
Colazal (balsalazide) - Brand		
Delzicol (mesalamine)		
Dipentum (olsalazine sodium)		
Giazo (balsalazide)		
Lialda (mesalamine)		
Pentasa (mesalamine)		
mesalamine		

### **APPROVAL CRITERIA**

Requests for a non-preferred 5-aminosalicylic acid (5-ASA) agent may be approved if the following criteria are met:

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

\*FHK- Florida Healthy Kids

- I. Individual has been on requested non-preferred 5-aminosalicylic acid (5-ASA) agent in the past 180 days (medication samples/ coupons/ discount cards are excluded from consideration as a trial); **OR**
- II. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to one preferred 5-ASA agent; **OR**
- III. The preferred 5-ASA agent is not FDA-approved for the prescribed indication and the request for the non-preferred agent is; **OR**
- IV. The preferred 5-ASA agent is not acceptable due to concomitant clinical situations, such as but not limited to the following:
  - A. Known hypersensitivity (such as but not limited to, active ingredients, salicylates, sulfonamides); **OR**
  - B. If the non-preferred agent is Pentasa and the individual has a diagnosis of Crohn's Disease with small bowel involvement (AHFS, DrugPoints BIIa).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.